Your browser doesn't support javascript.
loading
Driving Role of Interleukin-2-Related Regulatory CD4+ T Cell Deficiency in the Development of Lung Fibrosis and Vascular Remodeling in a Mouse Model of Systemic Sclerosis.
Frantz, Camelia; Cauvet, Anne; Durand, Aurélie; Gonzalez, Virginie; Pierre, Rémi; Do Cruzeiro, Marcio; Bailly, Karine; Andrieu, Muriel; Orvain, Cindy; Avouac, Jérôme; Ottaviani, Mina; Thuillet, Raphaël; Tu, Ly; Guignabert, Christophe; Lucas, Bruno; Auffray, Cédric; Allanore, Yannick.
Afiliação
  • Frantz C; Université de Paris, Inserm U1016, CNRS UMR 8104, and Cochin Hospital, Paris, France.
  • Cauvet A; Université de Paris, Inserm U1016, CNRS UMR 8104, Paris, France.
  • Durand A; Université de Paris, Inserm U1016, CNRS UMR 8104, Paris, France.
  • Gonzalez V; Université de Paris, Inserm U1016, CNRS UMR 8104, Paris, France.
  • Pierre R; Université de Paris, Inserm U1016, CNRS UMR 8104, Paris, France.
  • Do Cruzeiro M; Université de Paris, Inserm U1016, CNRS UMR 8104, Paris, France.
  • Bailly K; Université de Paris, Inserm U1016, CNRS UMR 8104, Paris, France.
  • Andrieu M; Université de Paris, Inserm U1016, CNRS UMR 8104, Paris, France.
  • Orvain C; Université de Paris, Inserm U1016, CNRS UMR 8104, Paris, France.
  • Avouac J; Université de Paris, Inserm U1016, CNRS UMR 8104, and Cochin Hospital, Paris, France.
  • Ottaviani M; INSERM UMR S 999, Hôpital Marie Lannelongue, and Université Paris-Saclay, Paris, France.
  • Thuillet R; INSERM UMR S 999, Hôpital Marie Lannelongue, and Université Paris-Saclay, Paris, France.
  • Tu L; INSERM UMR S 999, Hôpital Marie Lannelongue, and Université Paris-Saclay, Paris, France.
  • Guignabert C; INSERM UMR S 999, Hôpital Marie Lannelongue, and Université Paris-Saclay, Paris, France.
  • Lucas B; Université de Paris, Inserm U1016, CNRS UMR 8104, Paris, France.
  • Auffray C; Université de Paris, Inserm U1016, CNRS UMR 8104, Paris, France.
  • Allanore Y; Université de Paris, Inserm U1016, CNRS UMR 8104, and Cochin Hospital, Paris, France.
Arthritis Rheumatol ; 74(8): 1387-1398, 2022 08.
Article em En | MEDLINE | ID: mdl-35255201
ABSTRACT

OBJECTIVE:

Systemic sclerosis (SSc) is a debilitating autoimmune disease characterized by severe lung outcomes resulting in reduced life expectancy. Fra-2-transgenic mice offer the opportunity to decipher the relationships between the immune system and lung fibrosis. This study was undertaken to investigate whether the Fra-2-transgenic mouse lung phenotype may result from an imbalance between the effector and regulatory arms in the CD4+ T cell compartment.

METHODS:

We first used multicolor flow cytometry to extensively characterize homeostasis and the phenotype of peripheral CD4+ T cells from Fra-2-transgenic mice and control mice. We then tested different treatments for their effectiveness in restoring CD4+ Treg cell homeostasis, including adoptive transfer of Treg cells and treatment with low-dose interleukin-2 (IL-2).

RESULTS:

Fra-2-transgenic mice demonstrated a marked decrease in the proportion and absolute number of peripheral Treg cells that preceded accumulation of activated, T helper cell type 2-polarized, CD4+ T cells. This defect in Treg cell homeostasis was derived from a combination of mechanisms including impaired generation of these cells in both the thymus and the periphery. The impaired ability of peripheral conventional CD4+ T cells to produce IL-2 may greatly contribute to Treg cell deficiency in Fra-2-transgenic mice. Notably, adoptive transfer of Treg cells, low-dose IL-2 therapy, or combination therapy changed the phenotype of Fra-2-transgenic mice, resulting in a significant reduction in pulmonary parenchymal fibrosis and vascular remodeling in the lungs.

CONCLUSION:

Immunotherapies for restoring Treg cell homeostasis could be relevant in SSc. An intervention based on low-dose IL-2 injections, as is already proposed in other autoimmune diseases, could be the most suitable treatment modality for restoring Treg cell homeostasis for future research.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fibrose Pulmonar / Escleroderma Sistêmico Idioma: En Ano de publicação: 2022 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fibrose Pulmonar / Escleroderma Sistêmico Idioma: En Ano de publicação: 2022 Tipo de documento: Article